Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s): VYYRF

Healthcare Drug Manufacturers - Specialty & Generic

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.

TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > Distribution agreements

<< Previous

Bullboard Posts

Next >>

Post by whitenorth72on Jan 18, 2024 12:12pm

220 Views

Post# 35833808

Distribution agreements

I would imagine VM is going after everything that the competitors haven't secured. With the estimated 600M annual for the barium contrast market up for grabs with the imminent launch of Voyageurs complete set of products should make this year's venture extremely profitable.
At 2-5% of the market would be an excellent start.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 25, 2024